Company Overview of ChrysCapital
ChrysCapital is a private equity and venture capital firm specializing in management buy-outs or buy-ins, co-investments, public equity, PIPEs, growth capital in private and listed companies, and special situations including carve outs, joint ventures. The firm focuses on the business services; information technology; consumer goods and services; financial services; real estate; healthcare with a focus on pharmaceuticals, medical diagnostics and devices; infrastructure, power, and manufacturing sectors. It makes investments in companies based in or focusing on India and United States. The firm invests between $10 million and $300 million in companies with revenues ranging between $50 million...
Dr. Zakir Hussain Marg
New Delhi, 110 003
Founded in 1999
Key Executives for ChrysCapital
Managing Director and Chief Financial Officer
Managing Director and Managing Partner
Compensation as of Fiscal Year 2014.
ChrysCapital Key Developments
ChrysCapital Reportedly In Talks To Sell Mankind Pharma
Oct 14 14
ChrysCapital intends to sell its stake in Mankind Pharma Limited. ChrysCapital is holding talks to sell its 11% stake in Mankind Pharma. The potential buyers are all PE firms, including Temasek Holdings (Private) Limited, General Atlantic LLC, Actis Capital, LLP and Advent International Corporation. ChrysCapital hopes to fetch over $200 million for its 11% holding. Financial Services Monitor Worldwide added that Ramesh Juneja, Chief Executive Officer of Mankind, said in an email response: Regarding ChrysCapital seeking exit from Mankind you may directly speak with them because it is entirely their decision. ChrysCapital spokesperson Sanjiv Kaul declined comment.
Chryscapital-GIC Team Emerges As Front-Runner In Race To Buy Destimoney
Jun 16 14
A consortium of ChrysCapital and GIC Pte. Ltd. has emerged as the front-runner to purchase New Silk Route's (NSR) 100% stake in Destimoney Enterprises Private Limited. "They seem to have gained a clear edge over rival bidders", said a person directly involved with the transaction. The deal may value the company between INR 10 billion and INR 11 billion. NSR has mandated Morgan Stanley to sell Destimoney. Actis Capital, LLP and General Atlantic LLC had also participated in the bidding. While New Silk Route's Chief Executive Officer Parag Saxena did not reply to email questions on the subject, Destimoney's Managing Director and Chief Executive Officer Sudip Bandyopadhay declined comment.
ChrysCapital Presents at SuperReturn Emerging Markets 2014, Jun-26-2014 11:20 AM
Jun 10 14
ChrysCapital Presents at SuperReturn Emerging Markets 2014, Jun-26-2014 11:20 AM. Venue: The Okura Hotel, Amsterdam, Netherlands. Speakers: Gulpreet Kohli, Managing Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
Most Searched Private Companies
Sponsored Financial Commentaries